Bivision Pharma was founded by four scientists who brought in many years of R&D experience from drug design to market approvals in targeted radionuclide therapy (TRT). Their expertise and achievements in TRT inspired the founders to develop several highly correlated proprietary platforms for ligand screening, modulated coupling, and clinical translation. The parallel advancement and meaningful integration of these platforms have become the driving forces for the rapid progress of our pipeline.

Our first candidate is expected to move into clinical development earlier in 2023.